← Back to all trials
Recruiting
NCT07295717
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Conditions: Healthy Volunteers
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 76
Sponsor: Alnylam Pharmaceuticals
Location: Clinical Trial Site London
Summary
The purpose of this study is to:
* evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
* characterize the single-dose pharmacokinetics (PK) of ALN-4285
Eligibility Criteria
Inclusion Criteria:
* Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2
* Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has systolic blood pressure \>140 mmHg and/or a diastolic blood pressure \>90 mmHg
* Has an estimated glomerular filtration (eGFR) of \
Source: ClinicalTrials.gov (NCT07295717). StuddyBuddy aggregates publicly available trial information.
